Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Takeshi Yamashita, Thomas Laurent, Masaharu Kato, Nariaki Yoshihara & Fumiko Ono. (2020) Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization. Journal of Medical Economics 23:12, pages 1379-1388.
Read now
Read now
Christine G. Kohn, Gregory J. Fermann, W. Frank Peacock, Phil S. Wells, Christopher W. Baugh, Veronica Ashton, Concetta Crivera, Jeff R. Schein, Peter Wildgoose & Craig I. Coleman. (2017) Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Current Medical Research and Opinion 33:9, pages 1697-1703.
Read now
Read now
Lin Xie, Lien Vo, Allison Keshishian, Kwanza Price, Prianka Singh, Jack Mardekian, Amanda Bruno, Onur Baser, Jully Kim, Wilson Tan & Jeffrey Trocio. (2016) Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Journal of Medical Economics 19:8, pages 769-776.
Read now
Read now
Geno J. Merli, Judd E. Hollander, Patrick Lefebvre, François Laliberté, Monika K. Raut, Guillaume Germain, Brahim Bookhart & Charles V. Pollack. (2016) Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. Journal of Medical Economics 19:1, pages 84-90.
Read now
Read now
Joseph F. Dasta, Dominic Pilon, Samir H. Mody, Jessica Lopatto, François Laliberté, Guillaume Germain, Brahim K. Bookhart, Patrick Lefebvre & Edith A. Nutescu. (2015) Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. Journal of Medical Economics 18:12, pages 1041-1049.
Read now
Read now
Concetta Crivera, Winnie W. Nelson, Brahim Bookhart, Silas Martin, Guillaume Germain, François Laliberté, Jeffrey Schein & Patrick Lefebvre. (2015) Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Current Medical Research and Opinion 31:10, pages 1889-1895.
Read now
Read now
Amanda M. Farr, Yonghua Jing, Stephen Johnston, Jeffrey Trocio, Shalabh Singhal, Amanda Bruno & John Graham. (2015) Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hospital Practice 43:3, pages 172-179.
Read now
Read now
Gonzalo Barón-Esquivias, Francisco Fernández-Avilés, Felipe Atienza, Pablo Pastor Pueyo, Rocío Toro & Marcelo Sanmartín Fernández. (2015) Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 13:4, pages 341-353.
Read now
Read now
Geno J. Merli, Judd E. Hollander, Patrick Lefebvre, François Laliberté, Monika K. Raut, William H. Olson & Charles V. Pollack$suffix/text()$suffix/text(). (2015) Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hospital Practice 43:2, pages 85-93.
Read now
Read now
François Laliberté, Dominic Pilon, Monika K. Raut, Winnie W. Nelson, William H. Olson, Guillaume Germain, Jeff R. Schein & Patrick Lefebvre. (2014) Hospital Length of Stay of Nonvalvular Atrial Fibrillation Patients who Were Administered Rivaroxaban versus Warfarin with and without Pretreatment Parenteral Anticoagulants Therapies. Hospital Practice 42:3, pages 17-25.
Read now
Read now
François Laliberté, Dominic Pilon, Monika K. Raut, Winnie W. Nelson, William H. Olson, Guillaume Germain, Jeff R. Schein & Patrick Lefebvre. (2014) Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?. Current Medical Research and Opinion 30:8, pages 1521-1528.
Read now
Read now
Articles from other publishers (15)
Siti Norain Azahar, Saperi Sulong, Wan Asyraf Wan Zaidi, Norliza Muhammad, Yusof Kamisah & Norliana Masbah. (2022) Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study. International Journal of Environmental Research and Public Health 19:3, pages 1078.
Crossref
Crossref
Katherine VilainHaiyan LiWingham J. KwongElliott M. AntmanChristian T. RuffEugene Braunwald, David J. Cohen, Robert P. GiuglianoElizabeth A. Magnuson. (2020) Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes 13:11.
Crossref
Crossref
Tomohide Akase, Takanori Tsuchiya & Masami Morita. (2019) Hospitalization period and direct medical cost in patients using warfarin or novel oral anti‐coagulants after a cerebral embolism. International Journal of Clinical Pharmacy 41:2, pages 546-554.
Crossref
Crossref
Lara M. Groetzinger, Taylor J. Miller, Ryan M. Rivosecchi, Roy E. Smith, Mark T. Gladwin & Belinda N. Rivera-Lebron. (2018) Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis. Clinical and Applied Thrombosis/Hemostasis 24:6, pages 908-913.
Crossref
Crossref
Catherine A Saint, Michelle R Castelli, Andrew J Crannage, Zachary A Stacy & Erin K Hennessey. (2017) Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Medicine 5, pages 205031211771962.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Erin R. Weeda, W. Frank Peacock, Gregory J. Fermann, Christopher W. Baugh, Philip S. Wells, Veronica Ashton, Concetta Crivera, Peter Wildgoose, Jeff R. Schein & Craig I. Coleman. (2017) Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. International Journal of Clinical Practice 71:1, pages e12915.
Crossref
Crossref
Jeff R. Schein, C. Michael White, Winnie W. Nelson, Jeffrey Kluger, Elizabeth S. Mearns & Craig I. Coleman. (2016) Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal 14:1.
Crossref
Crossref
Erin R. Weeda, Christine G. Kohn, W. Frank Peacock, Gregory J. Fermann, Concetta Crivera, Jeff R. Schein & Craig I. Coleman. (2016) Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:10, pages 1109-1115.
Crossref
Crossref
Francois-Emery Cotté, Gwendoline Chaize, Anne-Françoise Gaudin, Adeline Samson, Alexandre Vainchtock & Laurent Fauchier. (2016) Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace 18:4, pages 501-507.
Crossref
Crossref
Kirsten M. Roberts, Tamara B. Knight, Eimeira Padilla-Tolentino, Manasa Murthy & Evan J. Peterson. (2015) Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study. Thrombosis 2015, pages 1-6.
Crossref
Crossref
Caitlyn Hurley, Shurui Dai & Diana M. Sobieraj. (2015) The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant na?ve, new-onset nonvalvular atrial fibrillation. International Journal of Cardiology 192, pages 1-2.
Crossref
Crossref
Fran?ois Lalibert?Michel Cloutier, Concetta Crivera, Winnie W. Nelson, William H. Olson, Jeffrey Schein, Julie Vanderpoel, Guillaume Germain & Patrick Lefebvre. (2015) Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation: An Observational Study From a Cohort of Matched Users. Clinical Therapeutics 37:3, pages 554-562.
Crossref
Crossref
Joseph F. Dasta, Dominic Pilon, Samir H. Mody, Jessica Lopatto, François Laliberté, Guillaume Germain, Brahim K. Bookhart, Patrick Lefebvre & Edith A. Nutescu. (2015) Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy. Thrombosis Research 135:2, pages 303-310.
Crossref
Crossref
Marlene Robinson. (2015) Non-Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care. Open Journal of Nursing 05:12, pages 1142-1157.
Crossref
Crossref